Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

RSS » New York Times News » NYTHealth

Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

July 23, 2025

18-fda-duchenne-mediumSquareAt3X-NJMqB0-rss

 The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Elevidys, after three patients died from liver failure after taking it or a similar treatment.  

Creator: The New York Times (NYTHealth)

Source URL

Related Posts

  • Public Awareness and Engagement
Immunization Awareness Importance: 5 Facts That Save Lives
Immunization Awareness Importance
  • Sustainable Practices
Environmental Action Steps: 6 Simple Ways That Work
Environmental Action Steps
  • Educational Resources
Environmental Education Classroom Importance: 5 Reasons
Environmental Education Classroom Importance

Most Recent

  • Book and Article Reviews
One Health Book Review: A Comprehensive Analysis 
One Health Book Review
  • Careers
Value of MPH in One Health: Career Benefits and Impact
Value of MPH in One Health
  • Community Stories
Malaria Control Strategies: One Health in Action
Malaria Control Community Stories

Spheres of Focus

Infectious Diseases

Climate & Disasters

Food &
Water

Natural
Resources

Built
Environments

Technology & Data

Featured Posts